Why Lockheed Martin Stock Keeps Going Down

Lockheed Martin fell 4% on Friday after missing Q earnings on both sales and EPS, with per-share profit $0.30 below analysts' forecasts and negative free cash flow for the quarter. Analysts at Susquehanna, Morgan Stanley, Bank of America, and RBC cut price targets to $700, $653, $600, and $575, while RBC kept only a "sector perform" rating. Despite a weak 0.6 book-to-bill ratio, management still expects 3% to 6% sales growth this year.

Analysis

The market is treating this as a clean fundamentals break, but the setup is more likely a timing mismatch than a secular de-rate. Defense primes often show lumpy bookings because contract awards and revenue recognition rarely line up quarter to quarter; when backlog is concentrated in missiles and munitions, one weak order print can look worse than the underlying demand environment. The important second-order effect is that a sustained production ramp tends to pressure near-term working capital before it helps revenue, so negative free cash flow is not automatically a demand alarm.

The bigger issue is sentiment, not solvency: once analysts cut targets in a group with low turnover and index ownership, you can get mechanical underownership and short-term multiple compression even if the long-cycle thesis is intact. That creates a window where peers with cleaner execution may see relative inflows, while suppliers with missile exposure can outperform if the ramp is real. The counterpoint is that if bookings stay weak for another 1-2 quarters, the market will stop giving management the benefit of the doubt and shift from “temporary timing” to “program execution risk.”

The contrarian read is that the weakest quarter may actually mark the point of maximum revision risk, because expectations have reset faster than the underlying Pentagon demand cycle. If management can show follow-through on multi-year missile capacity commitments by the next two reporting periods, the stock can re-rate quickly because the current multiple is already pricing in a moderation that may never show up. The main tail risk is not another earnings miss; it is evidence that the production rhetoric is not translating into booked backlog by mid-year.

Key Decisions for Investors

• Buy LMT on weakness with a 4-8 week horizon, using staged entry near post-earnings support; target a 10-15% rebound if the market reverts from 'miss/FCF panic' to 'backlog timing' framing, with a 6-8% stop if subsequent channel checks confirm no order recovery.
• Pair trade: long LMT / short a higher-multiple defense name with less missile exposure for 1-3 months, expressing the view that the selloff over-discounts an isolated booking miss while still keeping sector beta neutral; cut if relative underperformance persists after the next contract-award cycle.
• Buy out-of-the-money LMT calls 2-3 months out rather than stock if looking for a mean reversion trade; upside is convex if management guides to backlog normalization, while downside is capped to premium if bookings remain soft.
• Favor missile/small-munitions suppliers on any evidence of production ramp confirmation over the next earnings cycle; they should see the first-order benefit from capacity expansion before LMT fully monetizes it, giving a cleaner 1-2 quarter trade.
• Avoid chasing analyst downgrades in the next 1-2 weeks; if the stock stabilizes despite negative revisions, that would signal forced selling is largely done and create a better entry point than during the downgrade cascade.